Premium
H 1 ‐ and H 2 ‐antagonists in allergic and pseudoallergic diseases
Author(s) -
RING J.,
BEHRENDT H.
Publication year - 1990
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.1990.tb02460.x
Subject(s) - histamine , medicine , allergy , histamine h1 receptor , pharmacology , immunology , mast cell , receptor , antagonist
Summary Although known for more than 80 years, histamine still remains a fascinating substance for allergy research. Histamine antagonists have been in clinical use since 1942. The classical H 1 ‐antagonists with sedative side‐effects have been more or less replaced by newer non‐sedating H 1 ‐antagonists; the role of H 2 ‐receptors in allergic diseases is still controversial. There, are however, increasing reports of beneficial effects of H 2 ‐antagonists. mostly in combination with H 1 ‐antagonists, in a variety of allergic and pseudoallergic conditions such as chronic urticaria, anaphylactoid reactions due to colloid volume substitutes, opioid analgesics and radiographic contrast media. The combined use of H 1 ‐ and H 2 ‐antagonists might not only act as specific histamine antagonism but exert a mast cell stabilizing effect, as demonstrated in animal experiments and some clinical studies. Future research will show whether the combined use of H 1 ‐ and H 2 ‐anlagonists will become a routine therapeutic procedure in allergy therapy.